Cytokinetics will present aficamten trial results at the European Society of Cardiology Congress, including MAPLE-HCM findings.
Quiver AI Summary
Cytokinetics, Incorporated announced that it will present five studies related to aficamten at the European Society of Cardiology Congress 2025, held in Madrid from August 29 to September 1, 2025. Notable presentations include primary results from the MAPLE-HCM trial comparing aficamten and metoprolol in patients with obstructive hypertrophic cardiomyopathy (HCM) and a Late Breaking Clinical Science presentation on atrial fibrillation incidence across three trials involving aficamten. The company will also host an investor webcast on September 2, 2025, to discuss these and other findings. Aficamten, a cardiac myosin inhibitor, shows promise for regulatory approval following successful trial results, with ongoing evaluations in both obstructive and non-obstructive HCM, as well as related developments in heart failure therapies.
Potential Positives
- Positive results from MAPLE-HCM to be presented at a prestigious international conference, highlighting the company's research advancements.
- Opportunity to share findings from multiple clinical trials of aficamten, reinforcing its potential effectiveness in treating obstructive hypertrophic cardiomyopathy.
- Planned investor webcast to discuss primary results and additional data, demonstrating transparency and engagement with stakeholders.
Potential Negatives
- Forward-looking statements indicate potential risks and uncertainties, which may deter investor confidence in the company's future performance.
- The mention of adverse side effects or inadequate therapeutic efficacy raises concerns about the safety and effectiveness of aficamten.
- Competition from alternative therapies could impact the market potential for aficamten and other drug candidates, suggesting a challenging environment for the company.
FAQ
What are the MAPLE-HCM results being presented at ESC 2025?
The MAPLE-HCM results compare aficamten and metoprolol in patients with LVOT obstruction in obstructive hypertrophic cardiomyopathy.
When is the Cytokinetics investor webcast scheduled?
The investor webcast is scheduled for September 2, 2025, at 8:30 AM Eastern Time.
Who is presenting the primary results from MAPLE-HCM?
Pablo Garcia-Pavia, M.D., Ph.D., is presenting the primary results from MAPLE-HCM at ESC 2025.
How can I access the investor webcast for Cytokinetics?
You can register for the webcast online at the Cytokinetics investor website or view it in the Investors & Media section.
Where will the presentations on aficamten take place?
The presentations on aficamten will take place at the European Society of Cardiology Congress in Madrid, Spain.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CYTK Congressional Stock Trading
Members of Congress have traded $CYTK stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $CYTK stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN has traded it 2 times. They made 1 purchase worth up to $15,000 on 06/11 and 1 sale worth up to $15,000 on 06/17.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$CYTK Insider Trading Activity
$CYTK insiders have traded $CYTK stock on the open market 45 times in the past 6 months. Of those trades, 0 have been purchases and 45 have been sales.
Here’s a breakdown of recent trading of $CYTK stock by insiders over the last 6 months:
- ROBERT I BLUM (President & CEO) has made 0 purchases and 15 sales selling 148,361 shares for an estimated $6,082,894.
- ANDREW CALLOS (EVP, Chief Commercial Officer) has made 0 purchases and 9 sales selling 70,548 shares for an estimated $2,958,653.
- FADY IBRAHAM MALIK (EVP Research & Development) has made 0 purchases and 15 sales selling 39,066 shares for an estimated $1,531,882.
- WENDALL WIERENGA sold 20,000 shares for an estimated $769,200
- JOHN T HENDERSON sold 3,190 shares for an estimated $123,325
- EDWARD M. MD KAYE sold 3,636 shares for an estimated $116,715
- ROBERT ARTHUR HARRINGTON has made 0 purchases and 2 sales selling 1,350 shares for an estimated $55,993.
- MUNA BHANJI sold 1,454 shares for an estimated $43,227
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CYTK Hedge Fund Activity
We have seen 169 institutional investors add shares of $CYTK stock to their portfolio, and 213 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 7,647,189 shares (+76.8%) to their portfolio in Q2 2025, for an estimated $252,663,124
- MARSHALL WACE, LLP removed 2,007,567 shares (-99.0%) from their portfolio in Q2 2025, for an estimated $66,330,013
- POINT72 ASSET MANAGEMENT, L.P. removed 1,722,984 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $56,927,391
- WESTFIELD CAPITAL MANAGEMENT CO LP removed 1,310,336 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $43,293,501
- HOOD RIVER CAPITAL MANAGEMENT LLC removed 1,256,580 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $41,517,403
- DEERFIELD MANAGEMENT COMPANY, L.P. removed 1,160,315 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $38,336,807
- JANUS HENDERSON GROUP PLC removed 1,007,582 shares (-95.3%) from their portfolio in Q2 2025, for an estimated $33,290,509
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CYTK Analyst Ratings
Wall Street analysts have issued reports on $CYTK in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Buy" rating on 08/08/2025
- JP Morgan issued a "Overweight" rating on 06/09/2025
- Mizuho issued a "Outperform" rating on 05/29/2025
- Needham issued a "Buy" rating on 05/14/2025
- Barclays issued a "Overweight" rating on 05/08/2025
- RBC Capital issued a "Outperform" rating on 05/07/2025
- HC Wainwright & Co. issued a "Buy" rating on 04/21/2025
To track analyst ratings and price targets for $CYTK, check out Quiver Quantitative's $CYTK forecast page.
$CYTK Price Targets
Multiple analysts have issued price targets for $CYTK recently. We have seen 11 analysts offer price targets for $CYTK in the last 6 months, with a median target of $77.0.
Here are some recent targets:
- David Lebowitz from Citigroup set a target price of $77.0 on 08/08/2025
- Tessa Romero from JP Morgan set a target price of $53.0 on 06/09/2025
- Salim Syed from Mizuho set a target price of $84.0 on 05/29/2025
- Serge Belanger from Needham set a target price of $72.0 on 05/14/2025
- Gena Wang from Barclays set a target price of $53.0 on 05/08/2025
- Leonid Timashev from RBC Capital set a target price of $80.0 on 05/07/2025
- Ashwani Verma from UBS set a target price of $41.0 on 05/02/2025
Full Release
Positive Results from MAPLE-HCM to be Shared in Hot Line Presentation
Late Breaking Clinical Science Session to Present Incidence and Impact of Atrial Fibrillation Across Three Clinical Trials of Aficamten in Obstructive Hypertrophic Cardiomyopathy
Company to Host Investor Event and Webcast Tuesday September 2, 2025, at 8:00 AM Eastern Time
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations related to aficamten at the European Society of Cardiology Congress 2025 taking place in Madrid, Spain from August 29, 2025 – September 1, 2025 including a Hot Line presentation of the primary results from MAPLE-HCM ( M etoprolol vs A ficamten in P atients with L VOT Obstruction on E xercise Capacity in HCM ) and a Late Breaking Clinical Science presentation relating to the incidence and impact of atrial fibrillation across three clinical trials of aficamten in obstructive hypertrophic cardiomyopathy (HCM).
Oral Presentations
Title:
MAPLE-HCM:
Aficamten
vs
Metoprolol
in Obstructive HCM
Presenter:
Pablo Garcia-Pavia, M.D., Ph.D., Head of the Inherited Cardiac Diseases and Heart Failure Unit, Department of Cardiology, Hospital Universitario Puerta de Hierro and Full Professor, Centro Nacional de Investigaciones Cardiovasculares both in Madrid, Spain
Date:
August 30, 2025
Session Title:
Hot Line 2
Session Time:
8:15 - 9:45 AM CEST
Presentation Time:
9:18 AM CEST
Location:
Madrid (Main Auditorium)
Title:
REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM Trials: Incidence and Impact of Atrial Fibrillation in Obstructive HCM with
Aficamten
Presenter:
Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University
Date:
August 31, 2025
Session Title:
Late-Breaking Clinical Science: Cardiomyopathies
Session Time:
4:15-5:15 PM CEST
Presentation Time:
4:45 PM CEST
Location:
Budapest (Hall 10)
Title:
Efficacy and Safety of Long-Term Treatment with
Aficamten
in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results from FOREST-HCM
Presenter:
Sara Saberi, M.D., M.S., Associate Professor of Internal Medicine, University of Michigan Health Frankel Cardiovascular Center
Date:
August 31, 2025
Session Title:
Hypertrophic Cardiomyopathy: From Gene to Treatment
Session Time:
5:00 - 6:20 PM CEST
Presentation Time:
5:40 PM CEST
Location:
Science Box 4 (Research Gateway)
Title:
Effect of
Aficamten
Compared with
Metoprolol
on Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Pre-Specified Analysis of MAPLE-HCM
Presenter:
Sheila Hegde, M.D., M.P.H, Assistant Professor, UT Southwestern Medical Center, Dallas, TX, Affiliate Faculty, Brigham and Women's Hospital, Boston, MA
Date:
August 31, 2025
Session Title:
Hypertrophic Cardiomyopathy: From Gene to Treatment
Session Time:
5:00 - 6:20 PM CEST
Presentation Time:
6:10 PM CEST
Location:
Science Box 4 (Research Gateway)
Moderated Poster Presentation
Title:
Aficamten
in Patients with Obstructive Hypertrophic Cardiomyopathy: An Integrated Safety Analysis
Presenter:
Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University
Date:
August 30, 2025
Session Title:
Translating Improved Disease Understanding to Novel Therapies in Myocardial Disease
Session Time:
4:15 – 5:00 PM CEST
Location:
Station 8 (Research Gateway)
Investor Webcast Information
Cytokinetics will host an investor webcast on September 2, 2025, at 8:30 AM Eastern Time to discuss the primary results from MAPLE-HCM and other data presented at the European Society of Cardiology Congress 2025. Interested parties can register online at https://cytokinetics-esc-2025.open-exchange.net/ . The live webcast will be available on the Investors & Media section of the Cytokinetics website at www.cytokinetics.com . A replay of the webcast will be archived on the Cytokinetics website for six months.
About Cytokinetics
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. In addition, Cytokinetics is developing omecamtiv mecarbil , a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), ulacamten , a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X , LinkedIn , Facebook and YouTube .
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to any of our clinical trials, statements relating to the potential benefits of aficamten or any of our other drug candidates. Cytokinetics' research and development activities; the design, timing, results, significance and utility of preclinical and clinical results; and the properties and potential benefits of Cytokinetics' other drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval; Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics' ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics' drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.
CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
